Clear all

Refine your search

Content type
Tags
Firm name
Author
Jurisdiction
Language

810 results found

Article
Ask Lexy

Herbert Smith Freehills LLP | Australia | 29 Apr 2020

Commonwealth fails in its claim for compensation for PBS expenditure

Justice Nicholas’ long-awaited decision in Commonwealth v Sanofi is an Australian first. Of the 4 cases in Australia in which the Commonwealth has…
Article
Ask Lexy

Rothwell, Figg, Ernst & Manbeck, PC | USA | 18 Mar 2019

Jury Finds Amgen Antibody Patents Not Invalid

Over four years ago, in October 2014, Amgen initiated a patent infringement suit against Sanofi and Regeneron regarding biologics for treatment of…
Article
Ask Lexy

Rothwell, Figg, Ernst & Manbeck, PC | USA | 27 Feb 2019

The Third Time is the Charm for Sanofi in its IPR Challenge of Immunex’s ʼ487 Patent

On February 14, 2019, the PTAB issued final written decisions in two separate IPRs filed by Sanofi-Aventis, Genzyme Corp., and Regeneron…
Article
Ask Lexy

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | USA | 19 Feb 2019

The Plight of U.S. Pat. No. 8,679,487 at PTAB; if Two Arrows Miss the Mark, Launch a Third

Sanofi-Aventis U.S., LLC et al. V. Immunex Corp., IPR2017-01884 and IPR2017-01879 (P.T.A.B. Feb. 14, 2019) (HULSE, Moore, Obermann); see also denial…
Article
Ask Lexy

Jenner & Block LLP | USA | 17 Sep 2018

French Pharmaceutical Company Sanofi Agrees to Pay More Than $25 Million for FCPA Violations

On September 4, 2018, the French pharmaceutical company Sanofi S.A. (Sanofi) agreed to pay the US Securities and Exchange Commission (SEC) more than…
Article
Ask Lexy

FB Rice | USA | 29 May 2018

The challenge in obtaining broad antibody genus claims in the US

Functionally defined genus claims are vulnerable to invalidity based on lack of written description support, particularly where it is difficult to…
Article
Ask Lexy

Rothwell, Figg, Ernst & Manbeck, PC | USA | 3 Apr 2018

Global Approvals for Insulin Glargine Promise a More Affordable, Long-Acting Treatment for Diabetes

Last week, Mylan N.V. and Biocon Ltd. announced that their jointly-developed insulin glargine biosimilar, Semglee™, received marketing approval from…
Article
Ask Lexy

Buckley LLP | USA | 14 Mar 2018

Sanofi announces DOJ declination in FCPA investigation

As previously covered, French pharmaceutical company Sanofi S.A. announced in October 2014 that it was investigating whether certain payments made by…
Article
Ask Lexy

Barker Brettell LLP | USA | 7 Mar 2018

A Blow to Broad Antibody-to-Target Claims - The USPTO Follows Amgen Inc. v. Sanofi (Fed. Cir. 2017) and Issues New Guidance

Upon discovery of a novel biological target, for example in a newly characterised pathway, it is fairly common to attempt to patent protect an…
Commentary
Ask Lexy

Vaish Associates Advocates | India | 14 Dec 2017

CCI dismisses allegation of abuse of dominance against Sanofi

The Competition Commission of India (CCI) recently dismissed claims against Sanofi India Limited for alleged abuse of its dominant position in the market of drugs and pharmaceutical products. The CCI found that Sanofi enjoyed no dominant position and therefore held that there was no prima facie case to investigate its alleged conduct.
Previous page 1 2 3 ...